Αρχική World News Cancer Research UK reports record levels of investment in its spinouts

Cancer Research UK reports record levels of investment in its spinouts

Cancer Research UK reports its most successful financial year for its biotech spinout companies, despite pressures during the pandemic.

The charity’s commercial arm saw the amount of money from both internal and external sources invested in its spinouts more than double in the last year from £400m (2019/20) to £822m (2020/21). This takes the total investment to date to £2.3 billion, and the total number of spinouts created to over 60.

Cancer Research UK has built an incredible production line for cutting edge start-up companies — one of the most successful in the world.

– Iain Foulkes, chief executive officer of Cancer Research Technology and executive director of research and innovation at Cancer Research UK

Attracting investment is vital to allow spinouts to develop cancer therapies and diagnostics, increasing the likelihood that they will benefit patients sooner.

Notable spinout investments this financial year included ADC Therapeutics, Monte Rosa Therapeutics, Autolus Therapeutics and Achilles Therapeutics.

Star spinouts

ADC Therapeutics raised over £240m in capital and gained approval from the US Food and Drug Administration (FDA) in April this year for their lymphoma drug, Zynlonta. FDA approval means that the drug will now be available in the US to treat adults with diffuse large B cell lymphoma (DLBCL).

The FDA is responsible for regulating food and drug products to ensure that they are safe and effective for the US public. FDA approval often leads to fast-tracked approval of drugs in countries like the UK.

Monte Rosa Therapeutics, a biotechnology company specialising in potential drugs to target and destroy proteins essential for cancer survival, raised over £170m. One of Monte Rosa’s drug candidates for the treatment of lung cancer is currently undergoing studies to determine its safety and dosage for phase 1 clinical trials in humans.

Autolus Therapeutics, a biopharmaceutical company developing T cell therapies, a type of immunotherapy used to train your immune cells to recognise and kill cancer cells, raised £83m. One of Autolus’s drug candidates, based on early research funded by Cancer Research UK, is set to enter phase 1 clinical trials in early 2022, for the treatment of patients with neuroblastoma.

In addition, 2 Cancer Research UK spinouts managed to close their Initial Public Offering (IPO) this year. This milestone marks the ‘birth’ of a company in its public form, opening the company up to investors and increasing its ability to raise cash.

ADC Therapeutics closed its IPO at over $267.6m on the New York Stock Exchange (NYSE) in May last year. The NYSE, located in New York, is the oldest American exchange in existence and the largest stock exchange in the world.

And Achilles Therapeutics closed its IPO at $175.5m on NASDAQ in April this year. Unlike the NYSE, NASDAQ is a global electronic marketplace for buying and trading. The biopharmaceutical company — co-founded by Professor Charles Swanton, Cancer Research UK’s Chief Clinician — is developing T cell therapies to treat multiple types of solid tumours.

Speaking about his company, Achilles, Professor Swanton said: “Its success highlights just how exceptional Cancer Research UK is at bringing research out of the confinement of a lab and into the hands of patients.”

Achilles has 2 early-stage trials (phase 1/2a) ongoing, including testing their T cell therapy for patients with advanced non small lung cancer and melanoma that’s come back or spread to other parts of the body.

Any revenue that the charity generates from its commercial activities, including spinouts, is ploughed straight back into lifesaving cancer research. The report found that £36.4m in revenue was used for this purpose in the last financial year.

Innovating through a pandemic

The pandemic has shone a light on the life sciences sector as indispensable for tackling large-scale, complex health issues like cancer. And the UK Government’s backing of science and its call for the country to become a science superpower may also be creating a ‘halo’ effect for the sector.

Iain Foulkes said: “Despite an incredibly difficult year, we’ve shown the power of bringing researchers from academia and industry together in partnerships that will change human health for the better.

Our world class research, funded by the British public, is getting picked up by companies that develop tomorrow’s cancer treatments.

“These spinouts secure funding from investors around the world who believe in our science and the power of partnership. We are more committed than ever to bring those life-saving discoveries out of the lab and translate them into patient benefit.”

Read the full annual report for 2020/2021 from Cancer Research UK’s Commercial Partnerships to find out more about the charity’s commercial activities over the past financial year.

More on this topic

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Combining existing drugs improves prostate cancer survival

Adding abiraterone to standard hormone therapy improves survival for men with high-risk prostate cancer that’s not spread elsewhere in the body. “Today’s results are the...

New Combination of Old Drugs Improves Survival in Patients with Prostate Cancer [ESMO Congress 2021 Press Release]

LBA4_PR - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men...

Immunotherapy Prolongs Survival in Recurrent, Persistent or Metastatic Cervical Cancer [ESMO Congress 2021 Press Release]

LBA2_PR - Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: Randomized, double-blind, phase 3 KEYNOTE-826 study N. Colombo1, C....

Woman Diagnosed with Breast Cancer at 33 Launches Self-Examination App

Jessica Baladad has had a long history with self-examinations after a breast cancer scare in her early 20s. This habit helped save her life,...

Extended Adjuvant Treatment with Letrozole Results in Longer Survival in Postmenopausal Patients with Breast Cancer

According to results from a prospective, open-label, phase III study conducted in 69 Italian hospitals within the Gruppo Italiano Mammella among the postmenopausal patients...

Foodie Fridays: Apple Bok Choy Salad

While the temps may still be in the 80’s, apple season is upon us! Give this Apple Bok Choy salad a try!  It is...